The Predictive Safety Testing Consortium: A synthesis of the goals, challenges and accomplishments of the Critical Path.
In: Drug Discovery Today: Technologies, Jg. 4 (2007-06-01), Heft 2, S. 47-50
academicJournal
Zugriff:
The qualification of biomarkers of drug safety requires data on many compounds and nonclinical and clinical studies. The cost and effort associated with these qualifications cannot be easily covered by a single pharmaceutical company. Intellectual property associated with safety biomarkers is also held by many different companies. Consortia between different pharmaceutical companies can overcome cost and intellectual property hurdles to biomarker qualification. The Predictive Safety Testing Consortium (PSTC) is a collaborative effort between 16 different pharmaceutical companies to generate data supporting biomarker qualification. This Consortium is coordinated through the C-Path Institute, and currently has five biomarker qualification working groups engaged in this collaboration: nephrotoxicity, hepatotoxicity, vascular injury, myopathy, and non-genotoxic carcinogenicity. These working groups are aided by a data management team and a translational strategy team. Qualification studies of promising biomarkers are already progressing in several of the working groups, and results in the nephrotoxicity working group warranted a data submission to the FDA and EMEA for regulatory qualification of new nephrotoxicity biomarkers. [Copyright &y& Elsevier]
Copyright of Drug Discovery Today: Technologies is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
The Predictive Safety Testing Consortium: A synthesis of the goals, challenges and accomplishments of the Critical Path.
|
---|---|
Autor/in / Beteiligte Person: | Goodsaid, Federico M. ; Frueh, Felix W. ; Mattes, William |
Zeitschrift: | Drug Discovery Today: Technologies, Jg. 4 (2007-06-01), Heft 2, S. 47-50 |
Veröffentlichung: | 2007 |
Medientyp: | academicJournal |
ISSN: | 1740-6749 (print) |
DOI: | 10.1016/j.ddtec.2007.10.010 |
Schlagwort: |
|
Sonstiges: |
|